Evidence map›Paper›PMID 42282942›Full record

ArticleMolecular imaging

Low-Dose

Mengda Niu, Bai Yang, Xinxin Zhou, Jingjing Qin

Abstract read
In one paragraph

Article in Molecular imaging. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Mengda NiuCollege of Pharmacy, Chongqing Medical University, Chongqing, China.ORCID 0000-0003-3882-4745
Bai YangCollege of Pharmacy, Chongqing Medical University, Chongqing, China.ORCID 0009-0008-6068-6952
Xinxin ZhouSchool of Basic Medical Sciences, Chongqing Medical University, Chongqing, China.ORCID 0009-0006-1102-0113
Jingjing QinSchool of Basic Medical Sciences, Chongqing Medical University, Chongqing, China.ORCID 0009-0007-4062-8299

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The efficacy of chimeric antigen receptor (CAR)-T therapy in solid tumors is limited by the immunosuppressive microenvironment and poor T-cell infiltration. Radiotherapy offers immunomodulatory potential, yet its synergy with CAR-T via targeted internal radionuclides remains unexplored. Here, we identified protein regulator of cytokinesis 1 (PRC1) as a novel immunotherapeutic target. Through bioinformatic analysis, we engineered PRC1-specific CAR-T cells coexpressing the sodium iodide symporter (NIS) and an shRNA targeting SLC26A4, enabling enhanced iodide uptake and retention. These NIS-CAR-T cells demonstrated potent, antigen-restricted cytotoxicity and cytokine secretion upon co-culture with breast cancer cells. Low-dose

Indexed as

Breast NeoplasmsCell Cycle ProteinsImmunotherapy, AdoptiveIodine RadioisotopesReceptors, Chimeric AntigenSymportersT-LymphocytesAnimalsCell Line, TumorFemaleHumansMiceSodium-Iodide SymportersCell Cycle ProteinsIodine-125Iodine RadioisotopesPRC1 protein, humanReceptors, Chimeric AntigenSodium-Iodide SymportersSymporters125Ibreast cancerCAR-TNIS

Identifiers

PMID42282942
PMCPMC13250420

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.